Alternating two long-used bladder treatments cleared cancer in 24 of 25 patients whose disease had returned after BCG, an early study found. A larger trial comparing the approach with BCG alone is now enrolling.
News|Articles|February 24, 2026
Experts Preview Practice-Changing Data Ahead of 2026 ASCO GU
Author(s)Ryan Scott
Fact checked by: Alex Biese
Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.
Advertisement
Advertisement
As the cancer community gets ready for the 2026 ASCO Genitourinary (GU) Cancers Symposium, we at CURE are focusing on what the latest research could mean for people living with bladder, prostate, kidney, testicular and other genitourinary cancers. This annual meeting often brings news about new treatments, better ways to use current therapies and ways that may help doctors personalize care.
Related to this article
Chester Freeman reflects on hiding the scars from his childhood tumor surgeries for decades and finally feeling comfortable in his own skin at 60.
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.
After 19 years of survivorship, one cancer survivor reflects on life's changing seasons, managing scan anxiety and finding support beyond treatment.
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
Among more than 12,000 cancer survivors 65 and older, those who stayed physically active after diagnosis tended to have lower health care costs, an American Cancer Society study published Oct. 21, 2026, in CANCER found.
The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least 13 mutations per megabase.
Advertisement
Advertisement